In a focal cerebral ischemia model in mice deficient for TGF-β-activated kinase 1 (TAK1) in microglia/macrophages, a study demonstrated that EPO administration improved clinical outcomes and dampened stroke-induced activation of TAK1 and inflammasome cascades (Heinisch et al., 2021). This evidence concerns the gene EPO and Cerebral ischemia.